Search Results
Your search for ,USE matches 11182 pages
Showing 4201 - 4250Trends in Deaths From Cutaneous Melanoma in the United States
Recent treatment advances in metastatic melanoma resulted in reductions in population-level mortality from the disease, according to a study published by Polsky et al in the American Journal of Public Health. Methods Researchers analyzed new cases and deaths from melanoma from nine U.S....
Does Aspirin Use Lower the Risk of Hepatocellular Carcinoma and Liver-Related Mortality in Patients With Chronic Viral Hepatitis?
In a study reported in The New England of Medicine, Tracey G. Simon, MD, MPH, and colleagues found that low-dose aspirin use was associated with a reduced risk of hepatocellular carcinoma and liver-related mortality among patients with chronic hepatitis B or C infection. Study Details The study...
COVID-19 May Remain Stable for Hours to Days in Aerosols and on Surfaces
The virus that causes coronavirus disease 2019 (COVID-19) is stable for several hours to days in aerosols and on surfaces, according to a new study published as a research letter in The New England Journal of Medicine. A team of researchers from the National Institutes of Health (NIH); the Centers ...
Continuous Coverage of COVID-19
The staff of The ASCO Post recognizes the steady flow of news on the novel coronavirus, or COVID-19. Here, we've compiled a list of links to articles and resources on the COVID-19 pandemic. If you have a report you'd like to share, please e-mail it to us at editor@ascopost.com. Direct From ASCO:...
Strategies for Protecting Patients and Health-Care Providers Against COVID-19
For Patients Patients undergoing active treatment for cancer and cancer survivors may be at increased risk of becoming infected with the coronavirus because of their compromised immune system and their susceptibility to other illnesses. ASCO has developed information on Cancer.Net on how patients...
Mitigating the Spread of COVID-19 and Its Impact on Cancer
On March 11, the World Health Organization (WHO) took the step it had been avoiding for weeks and declared that the spread of the coronavirus disease 2019 (COVID-19), and the virus that causes it, now identified as SARS-CoV-2, had reached global pandemic levels, the first pandemic sparked by a...
Selected Abstracts on Novel Treatments in Colon, Hepatocellular, and Biliary Tract Cancers
The ASCO Post has reported on the pivotal trials presented at the 2020 Gastrointestinal Cancers Symposium in several issues. Featured here are the findings of several additional abstracts worthy of mention. Intermittent Oxaliplatin in Stage II or III Colon Cancer As adjuvant treatment for stage II...
Risk of Cervical Cancer With Different Types of Intrauterine Devices
Patients who used copper intrauterine devices (IUDs) were found to have a lower risk of high-grade cervical neoplasms vs users of the levonorgestrel-releasing intrauterine system, according to a study published by Spotnitz et al in the journal Obstetrics & Gynecology. The study notes that more...
New ASCO Guideline Highlights the Management of Male Breast Cancer
THE ANNUAL INCIDENCE of male breast cancer in the United States is dwarfed by the rate among women. Yet, for the estimated 2,670 men who will be diagnosed with breast cancer this year, life-extending and life-enhancing treatments are crucial.1 To help reduce knowledge gaps and improve mortality and ...
Study Focuses on Role of Microbes in Pancreatic Cancer
Although bacteria are predominant in the gastrointestinal tract, they also reside on and in other parts of the body, including some unexpected places, such as malignant tumors. There are numerous reports of this phenomenon, but most have not identified a functional role for the microbes. In the...
FDA Pipeline: Breakthrough Therapy for NSCLC With Specific Mutation, Approval of Test for Cervical Cancer, and More
Over the past week, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to a bispecific antibody for the treatment of patients with metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations; granted approval to a test for human...
Conventionally Fractionated vs Moderate Hypofractionated Radiation Therapy for Localized Prostate Cancer: Long-Term Update
As reported in the Journal of Clinical Oncology by Avkshtol et al, the 10-year update of a single-center trial has confirmed the primary analysis of the study, showing no superiority in 5-year biochemical and/or clinical disease failure rate with moderate hypofractionated intensity-modulated...
Annual Report to the Nation on the Status of Cancer Released
The Annual Report to the Nation on the Status of Cancer has found that cancer death rates continued to decline from 2001 to 2017 in the United States for all cancer sites combined. The report was published by Hensley et al in the journal Cancer. The annual report is a collaborative effort among the ...
HAPLO2019: Advances in Haploidentical Transplantation and Other Novel Cellular Therapies
Now in its seventh year, the Haploidentical Transplant Symposium (HAPLO) continues to explore advances in haploidentical and other novel cellular therapies. The most recent of these meetings—HAPLO2019—met in Orlando, Florida, 2 days before the start of the 2019 American Society of Hematology (ASH)...
Survival Benefits Achieved With Pembrolizumab in MSI-H and CPS ≥ 10 Gastric/Gastroesophageal Junction Cancer
Post hoc subanalyses of three KEYNOTE trials established the survival benefit of pembrolizumab in advanced gastric/gastroesophageal junction cancer with microsatellite instability–high (MSI-H) tumors or a programmed cell death ligand 1 (PD-L1) combined positive score (CPS) ≥ 10 (ie, the number of...
Expert Point of View: Navid Hafez, MD, MPH
Ilixadencel is essentially a dendritic cell vaccine without preloaded antigens. In the MERECA study, ilixadencel produced “a great signal,” though this approach is still very experimental, said the study’s invited discussant, Navid Hafez, MD, MPH, of Yale Cancer Center. Dr. Hafez is a member of the ...
Evaluation of Different Methods of Biopsy for the Diagnosis of Prostate Cancer
In a study reported in The New England Journal of Medicine, Ahdoot et al found that combined use of magnetic resonance imaging (MRI)-targeted biopsy and 12-core systematic prostate biopsy led to enhanced detection of prostate cancers vs either approach alone in men with MRI-visible prostate...
Conquer Cancer–Funded Researcher’s Pancreatic Cancer Study Highlighted in ASCO’s Clinical Cancer Advances 2020
The work of nine researchers who have previously received funding from Conquer Cancer is featured in ASCO’s Clinical Cancer Advances 2020. Visit CONQUER.ORG for more details. Advance of the Year: Refinement of Surgical Treatment At Massachusetts General Hospital, Janet Murphy, MD, is expanding...
Zelia M. Correa, MD, PhD, Joins Sylvester Comprehensive Cancer Center and Bascom Palmer Eye Institute
An expert in ocular oncology, Zelia M. Correa, MD, PhD, has joined Sylvester Comprehensive Cancer Center and Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine as Co-Director of the Ocular Oncology Service. Dr. Correa specializes in the diagnosis and treatment of eye...
Tazemetostat for Advanced Epithelioid Sarcoma
On January 23, 2020, tazemetostat was granted accelerated approval for the treatment of adults and pediatric patients aged 16 and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.1,2 Supporting Efficacy Data Approval was based on the finding of...
Selected ASH Abstracts on Novel Treatments in Acute Lymphoblastic Leukemia
To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapies for newly diagnosed and relapsed or refractory acute...
Avapritinib for Gastrointestinal Stromal Tumor With PDGFRA Exon 18 Mutation
On January 9, 2020, avapritinib was approved for treatment of adults with unresectable or metastatic gastrointestinal stromal tumors (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including D842V mutations.1,2 It is the first therapy approved for...
Brief Highlights From the 2019 San Antonio Breast Cancer Symposium
In addition to our regular coverage of the 2019 San Antonio Breast Cancer Symposium, the following reports from the meeting include studies you may have missed. We hope you find them of interest. Ribociclib/Letrozole as Neoadjuvant Therapy As neoadjuvant therapy in women with high-risk hormone...
Treating Patients With Chronic Lymphocytic Leukemia in 2020
With the availability of a number of effective targeted agents for the treatment of chronic lymphocytic leukemia (CLL), the question arises whether chemotherapy still has a role in treating this malignancy. At the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, CLL...
ASCO’s TAPUR Study: Biomarker-Driven Treatment Paying Off in Colorectal Cancer
New data presented at the 2020 Gastrointestinal Cancers Symposium are validating the purpose of ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) study, a multibasket trial that matches patients’ genomic alterations to commercially available targeted therapies. The aim is to learn...
ASCO and CAP Release Updated Guideline on Estrogen and Progesterone Testing in Breast Cancer
ASCO and the College of American Pathologists (CAP) have jointly published an update to a clinical practice guideline on estrogen receptor and progesterone receptor testing in breast cancer.1 The guideline for immunohistochemistry testing of estrogen receptor and progesterone receptors in patients...
Expert Point of View: Daniel Geynisman, MD
Formal discussant of this trial of MK-6482, Daniel Geynisman, MD, of Fox Chase Cancer Center, Philadelphia, was enthusiastic about this presentation. “The response rates were fabulous in this group of heavily pretreated patients,” he stated. “A total of 69% had some tumor shrinkage, 24% had an...
Expert Point of View: Jarushka Naidoo, MBBCh
“The investigators of the current study tested the hypothesis that vitamin D supplementation is associated with a reduced risk of checkpoint-induced colitis by rigorously assessing 37 variables in both discovery and validation cohorts,” said invited discussant Jarushka Naidoo, MBBCh, Assistant...
Expert on Public Health and Policy Looks at Precision Oncology
A study published in JAMA Oncology found that 31 genome-targeted anticancer agents were in use as of January 2018.1 To shed light on the current state of precision oncology, The ASCO Post recently spoke with David M. Cutler, PhD, the Otto Eckstein Professor of Applied Economics in the Department of ...
FDA Pipeline: Priority Review in DLBCL, Fast Track Designations in T-Cell Lymphoma and Adenoid Cystic Carcinoma
Over the past week, the U.S. Food and Drug Administration (FDA) granted Priority Review to a combination therapy in diffuse large B-cell lymphoma (DLBCL); gave Fast Track designations for treatments in T-cell lymphoma and adenoid cystic carcinoma; granted Orphan Drug designation to an agent for the ...
Former FDA Commissioner Scott Gottlieb, MD, Relays Opinions on Coronavirus
Scott Gottlieb, MD, former Commissioner of the U.S. Food and Drug Administration (FDA), had some advice for attendees of the 37th Annual Miami Breast Cancer Conference in his keynote address at the meeting. While his formal presentation pertained to innovations in oncology drug development and...
NSABP B-42 Trial 10-Year Update: Impact of Extended Letrozole on Disease-Free Survival
“In the 10-year analysis of the NSABP B-42 trial, the effect of extended treatment with 5 years of letrozole on disease-free survival persisted and reached statistical significance. There was no significant improvement in overall survival with letrozole, but letrozole continued to provide a...
Investigators in Brazil Explore Availability, Cost, and Use of Biosimilar Trastuzumab in Patients With HER2-Positive Breast Cancer
Investigators in Brazil are seeking to explore the efficacy and safety of adjuvant biosimilar trastuzumab in a real-world study of patients with early HER2-positive breast cancer. In 2019, biosimilar trastuzumab became the first biosimilar approved in Brazil for the treatment of patients with...
Phase III KEYNOTE-522: Pembrolizumab Benefits Outcome in Neoadjuvant, Adjuvant Settings in Triple-Negative Breast Cancer
In patients with triple-negative breast cancer, the addition of pembrolizumab to neoadjuvant and adjuvant chemotherapy achieves higher rates of pathologic complete response compared with placebo, according to results of the phase III KEYNOTE-522 trial presented at the 2019 San Antonio Breast Cancer ...
Adding Capecitabine to Systemic Therapies Improves Outcomes in Triple-Negative Breast Cancer
Capecitabine improves disease-free and overall survival for patients with triple-negative breast cancer, but only when it is added to other systemic therapies, not when it is used as a substitute, according to a large meta-analysis of the effects of capecitabine in early breast cancer, The results...
Conference Highlights From the 2019 San Antonio Breast Cancer Symposium
More than 7,500 specialists in breast oncology from over 90 countries attended the 2019 San Antonio Breast Cancer Symposium (SABCS) held last December. Researchers convened to present a wide-ranging array of abstracts and posters featuring important new data in the treatment of breast cancer....
Phenelzine for Biochemical Recurrent Castration-Sensitive Prostate Cancer
A monoamine oxidase A (MAOA) inhibitor in use for decades as an antidepressant demonstrated activity in patients with recurrent prostate cancer, with most toxicities seen with the treatment being reported as mild. These findings were published by Gross et al in Prostate Cancer and Prostatic...
Anthracycline-Based Chemotherapy vs Docetaxel/Capecitabine: What’s the Better Adjuvant Therapy for Early Breast Cancer?
As reported in the Journal of Clinical Oncology by Delaloge et al, a second randomized component of the phase III EORTC 10041/BIG 3-04 MINDACT trial, though underpowered, suggested no benefit of docetaxel/capecitabine vs standard anthracycline-based adjuvant therapy for patients with early breast...
Early FDG-PET Allows De-escalation of Chemotherapy in Metastatic Seminoma
In patients with metastatic seminoma, the early use of 18F-fluorodeoxyglucose (FDG)–positron-emission tomography (PET) to risk-stratify patients enabled the de-escalation of chemotherapy, avoiding treatment with bleomycin—one of the most toxic drugs used to treat this cancer—and excessive doses of...
Concurrent Pembrolizumab and Chemoradiotherapy in Locally Advanced NSCLC
In a phase I trial reported in JAMA Oncology, Jabbour et al found that the use of pembrolizumab concurrently with chemoradiotherapy in advanced non–small cell lung cancer (NSCLC) was tolerable, and that progression-free survival with the combination therapy was 69.7% at 12 months. As stated by the...
Geographic and Racial Variability in Germline BRCA Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer
In a study reported in the Journal of Clinical Oncology, Talia Golan, MD, and colleagues identified geographic and ethnic heterogeneity of germline BRCA1/2 mutation prevalence among patients screened for entry into the phase III POLO trial, which examined the efficacy of olaparib maintenance...
Gopal K. Bajaj, MD, MBA, on Reducing Opioid Use in Patients With Head and Neck Cancer Undergoing Radiotherapy
Gopal K. Bajaj, MD, MBA, of the Inova Schar Cancer Institute, discusses the results of a small study that showed prophylactic gabapentin can be safely and effectively used to significantly reduce pain and the use of opioids in patients undergoing radiotherapy or chemoradiotherapy for head and neck...
Expert Point of View: Daniel V.T. Catenacci, MD
Daniel V.T. Catenacci, MD, Associate Professor of Medicine and Director of the Gastrointestinal Oncology Program at the University of Chicago, was the JAVELIN Gastric 100 study’s invited discussant. After offering an extensive background on the use of immunotherapy in gastric or gastroesophageal...
Malnutrition Evaluation Before Oncologic Surgery
The best approach for surgeons to identify malnourished patients with cancer before they have major oncologic surgery may be specifically related to the type of cancer the patient has, according to researchers who found that common definitions of malnutrition do not apply equally to all cancers in...
Initiative to Reduce PET/CT Radiotracer Infiltrations
In a single-institution study reported in JCO Oncology Practice, Kiser et al found that implementation of a quality improvement plan significantly reduced the frequency of positron-emission tomography (PET)/computed tomography (CT) radiotracer infiltration among a team of technologists....
Neoadjuvant and Adjuvant Pembrolizumab in Early Triple-Negative Breast Cancer
As reported in The New England Journal of Medicine by Peter Schmid, MD, PhD, and colleagues, interim analyses of the phase III KEYNOTE-522 trial have shown that the addition of pembrolizumab to neoadjuvant chemotherapy and use of adjuvant pembrolizumab vs placebo resulted in improvements in...
Francis P. Worden, MD, on the Role of Induction Chemotherapy in Laryngeal Preservation
Francis P. Worden, MD, of the University of Michigan Health System Comprehensive Cancer Center, explores the use of novel biomarkers that may help predict response to induction chemotherapy and survival in patients with locally advanced laryngeal cancer.
Active Hexose Correlated Compound
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Gary Deng, MD, PhD, and Jyothirmai Gubili, MS, focus on active hexose...
New Guideline Tackles Rapidly Evolving Imaging Strategies for Advanced Prostate Cancer
Advances in radiology and molecular imaging have the potential to significantly change how clinicians diagnose, stage, and monitor response to therapy in patients with prostate cancer. However, there are limited data comparing these next-generation imaging modalities to each other and to...
FDA Pipeline: Priority Review in Lung Cancer, Breakthrough Therapy Designation in Head and Neck Cancer, and More
This week, the U.S. Food and Drug Administration (FDA) granted Priority Review to brigatinib for the treatment of ALK-positive lung cancer and Breakthrough Therapy designation to a potential first-in-class oral antagonist of inhibitors of apoptosis proteins for the treatment of head and neck...
